|
Report No. : |
337626 |
|
Report Date : |
20.08.2015 |
IDENTIFICATION DETAILS
|
Name : |
PHARMACHEMIE B.V. |
|
|
|
|
Registered Office : |
Swensweg 5 2031GA Haarlem |
|
|
|
|
Country : |
Netherlands |
|
|
|
|
Financials (as on) : |
31.12.2014 |
|
|
|
|
Date of Incorporation : |
15.03.1944 |
|
|
|
|
Com. Reg. No.: |
34016881 |
|
|
|
|
Legal Form : |
Private company |
|
|
|
|
Line of Business : |
|
|
|
|
|
No. of Employee : |
565 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
Slow but correct |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Netherland |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
NETHERLANDS ECONOMIC OVERVIEW
The Netherlands, the sixth-largest economy in the European Union,
plays an important role as a European transportation hub, with a persistently
high trade surplus, stable industrial relations, and moderate unemployment.
Industry focuses on food processing, chemicals, petroleum refining, and
electrical machinery. A highly mechanized agricultural sector employs only 2%
of the labor force but provides large surpluses for food-processing and
underpins the country’s status as the world’s second largest agricultural
exporter. The Netherlands is part of the Eurozone, and as such, its monetary
policy is controlled by the European Central Bank. The Dutch financial sector
is highly concentrated, with four commercial banks possessing over 90% of
banking assets. The sector suffered as a result of the global financial crisis
and required billions of dollars of government support, but the European
Banking Authority completed stringent reviews in 2014 and deemed Dutch banks to
be well-capitalized. To address the 2009 and 2010 economic downturns, the
government sought to stimulate the domestic economy by accelerating
infrastructure programs, offering corporate tax breaks for employers to retain
workers, and expanding export credits. The stimulus programs and bank bailouts,
however, resulted in a government budget deficit of 5.3% of GDP in 2010 that
contrasted sharply with a surplus of 0.7% in 2008. The government of Prime
Minister Mark RUTTE has since implemented significant austerity measures to
improve public finances and has instituted broad structural reforms in key
policy areas, including the labor market, the housing sector, the energy
market, and the pension system. As a result, the government budget deficit at
the end of 2014 dropped to 1.8% of GDP. Following a protracted recession during
which unemployment doubled to 7.4% and household consumption contracted for
nearly three consecutive years, the year 2014 saw fragile GDP growth of 0.8
percent and a rise in most economic indicators. Drivers of growth included
increased exports and business investments, as well as newly invigorated
household consumption.
|
Source
: CIA |
Company name PHARMACHEMIE
B.V.
Operative address Swensweg
5
2031GA Haarlem
Netherlands
Status Active
Specification This
company can meet all its obligations.
Legal form Private company
Registration number KvK-nummer:
34016881
VAT-number 001012940
Year
2014 Mutation 2013
Mutation
Fixed assets 95.601.000 16,21 82.266.000
Total receivables 432.621.000 132,23186.287.000
Total equity 208.928.000 607,25 29.541.000
Short term liabilities 465.597.000 27,16366.155.000
Net result -55.778.000
-188.466,60 -29.580
Working capital 115.264.000
1.184,63 -10.627.000
Quick ratio 0,97 56,45 0,62
Company name Pharmachemie
B.V.
Trade names Pharmachemie
B.V.
Teva Pharmachemie
Teva Pharmachemie Operations
Operative address Swensweg
5
2031GA Haarlem
Netherlands
Correspondence address Postbus
552
2003RN Haarlem
Netherlands
Telephone number 08000228400
Fax number 0235147192
Email address pch.legal@tevapharmachemie.com
Registration number 34016881
Branch number 000016614496
VAT-number 001012940
Status Active
First registration
company register 1959-12-23
Memorandum 1959-12-23
Establishment date 1944-03-15
Legal form Private company
Legal person since 1972-04-25
Last proposed
admendment 2014-11-19
Issued placed capital EUR
354.150
Paid up share capital EUR
354.150
Activities
SBI Manufacture of pharmaceutical preparations
Wholesale of pharmaceutical goods
Other specialised business services
Company name Pharmachemie B.V.
Trade names Pharmachemie B.V.
Teva
Pharmachemie
Teva Pharmachemie
Operations
Operative address Swensweg 5
2031GA
Haarlem
Netherlands
Correspondence address Postbus 552
2003RN
Haarlem
Netherlands
Telephone number
08000228400
Fax number 0235147192
Email address
pch.legal@tevapharmachemie.com
Registration number 34016881
Branch number
000016614496
VAT-number 001012940
Status Active
First registration company register 1959-12-23
Memorandum 1959-12-23
Establishment date 1944-03-15
Legal form Private company
Legal person since 1972-04-25
Last proposed admendment 2014-11-19
Issued placed capital EUR 354.150
Paid up share capital EUR 354.150
SBI Manufacture of pharmaceutical preparations (2120)
Wholesale
of pharmaceutical goods (46461)
Other
specialised business services (7490)
ISO certified Yes
Exporter No
Importer No
Goal Import and export, wholesale, manufacturing, and making manufacture of
pharmaceutical products, raw materials and products and the acquisition,
provision and operation of licenses, patents, trademarks and other forms of
industrial property Establish the , to participate in, managing, advising,
checking, to collaborate with, the conduct of the management board and the
provision of services to other vennnootschappen and enterprises and to finance
other enterprises and companies
Shareholders Teva Pharmaceuticals Europe B.V.
Piet
Heinkade 107
1019GM
Amsterdam
Netherlands
Registration
number: 301106250000
Percentage:
100%
ratiopharm
nederland B.V.
Registration
number: 300636290000
Teva
Nederland B.V.
Registration
number: 340961910000
Teva
Pharma B.V.
Registration
number: 300993690001
Teva
B.V.
Registration
number: 302098140000
Companies on same address
Teva
Pharmaceuticals Eur. B.V.
Registration
number: 301106250002
Liability statements Teva Pharma B.V.
Swensweg
5
2031GA
Haarlem
Netherlands
Registration
number: 300993690001
date
of issue: 2008-03-13
Starting
date: 2008-02-01
End
date: 2012-12-31
ABN Amro Bank NV
Account number: NL76ABNA0486211401
BIC: ABNANL2A
ABN Amro Bank NV
Account number: 43.27.24.478
BIC: ABNANL2A
ING Bank NV
Account number: NL81INGB0006494361
BIC: INGBNL2A
ING Bank NV
Account number: NL48INGB0000188985
BIC: INGBNL2A
Active management
Teva
Pharmaceuticals Europe B.V.
Piet
Heinkade 107
1019GM
Amsterdam
Netherlands
Registration
number: 301106250000
Competence:
Jointly authorized
Function:
Manager
Starting
date: 2006-10-03
H.P.J.
Henrichs (Henri Pieter Josephus)
Netherlands
Competence:
Jointly authorized
Function:
Manager
Starting
date: 2014-08-01
Date
of birth: 1954-06-03, Amsterdam, NL
J.P.
Dalderop (Johannes Paulus)
Netherlands
Competence:
Jointly authorized
Function:
Manager
Starting
date: 2014-08-01
Date
of birth: 1957-06-04, Utrecht, NL
H.C.
Diekema (Hendrik Cornelis)
Netherlands
Competence:
Limited authorization
Function:
Proxy
Starting
date: 2010-07-01
Date
of birth: 1963-10-06, Ede, NL
M.T.
Prinsen - Fris (Maria Theresia)
Netherlands
Competence:
Limited authorization
Function:
Proxy
Starting
date: 2010-07-01
Date
of birth: 1967-02-13, Haarlem, NL
J.W.
van Wijk (Jan Willem)
Netherlands
Competence:
Limited authorization
Function:
Proxy
Starting
date: 2012-07-03
Date
of birth: 1962-10-17, Haarlem, NL
J.M.
Maaskant (Johanna Maria)
Netherlands
Competence:
Limited authorization
Function:
Proxy
Starting
date: 2012-07-03
Date
of birth: 1963-06-02, Haarlem, NL
M.A.
Ince - Groenhof (Mirjam Anselma)
Netherlands
Competence:
Limited authorization
Function:
Proxy
Starting
date: 2012-07-03
Date of birth: 1965-06-16, Haarlem, NL
Year 2015
2014 2013
2012 2011
Total 565 565 560 565 565
Score 5.65
Description Payments are
Slow but Correct
Year 2014
2013
Quick ratio 0,97 0,62
Current ratio 1,25 0,97
Working capital/ balance total 0,17 -0,02
Equity / balance total 0,31 0,07
Equity / Fixed assets 2,19 0,36
Equity / liabilities 0,45 0,07
Balance total / liabilities 1,45 1,07
Working capital 115.264.000 -10.627.000
Equity 208.928.000 29.541.000
Mutation equity 607,25
Mutation short term liabilities 27,16
Return on total assets (ROA) -11,10 -0,01
Return on equity (ROE) -35,94 -0,12
Gross profit margin -24,27
-0,01
Net profit margin -21,92 -0,01
Average collection ratio 0,55 0,80
Average payment ratio 0,59 1,58
Equity turnover ratio 1,22 9,96
Total assets turnover ratio 0,38 0,67
Fixed assets turnover ratio 2,66
3,58
Inventory conversion ratio 1,95 2,31
Turnover 254.508.000 294.355.000
Year 2014
2013
Gross margin 1.549.000
37.708.000
Operating result -61.769.000 -35.483.000
Net
result after taxes
-55.778.000 -29.580.000
Summary The 2014 financial result structure is a postive
working capital of 115.264.000 euro, which is in agreement with 17 % of the
total assets of the company.
The
working capital has increased with 1184.63 % compared to previous year. The
ratio, with respect to the total assets of the company has however, increased.
The
improvement between 2013 and 2014 has mainly been caused by an increase of the
current assets.
The
current ratio of the company in 2014 was 1.25. When the current ratio is below
1.5, the company may have problems meeting its short-term obligations.
The
quick ratio in 2014 of the company was 0.97. A company with a Quick Ratio of
less than 1 cannot currently pay back its current liabilities.
The 2013 financial result structure is a negative working
captial of -10.627.000 euro, which is in
agreement with -2 % of the total assets of the company.
The
current ratio of the company in 2013 was 0.97. When the current ratio is below
1.5, the company may have problems meeting its short-term obligations.
The
quick ratio in 2013 of the company was 0.62. A company with a Quick Ratio of
less than 1 cannot currently pay back its current liabilities.
Last annual account 2014
Remark annual account The company is obliged to file its financial
statements.
Type of annual account Consolidated
Annual account Pharmachemie B.V.
Swensweg
5
2031GA
Haarlem
Netherlands
Registration
number: 340168810000
Year 2014
2013
End date 2014-12-31 2013-12-31
Intangible fixed assets 8.259.000 13.341.000
Tangible fixed assets 86.270.000 67.776.000
Financial fixed assets 1.072.000 1.149.000
Fixed assets 95.601.000 82.266.000
Total stock 130.759.000 127.580.000
Total receivables 432.621.000 186.287.000
Liquid funds 17.481.000 41.661.000
Current assets 580.861.000 355.528.000
Total assets 676.462.000 437.794.000
Total equity 208.928.000 29.541.000
Long term liabilities 1.937.000 42.098.000
Short term liabilities 465.597.000 366.155.000
Total short and long term liab 467.534.000 408.253.000
Total liabilities 676.462.000 437.794.000
Summary The total assets of the company increased with
54.52 %between 2013 and 2014.
The
fixed asset growth of 16.21 % is lower than the total asset growth.
The
asset growth has mainly been financed by a Net Worth increase of 607.25 %.
Debt, however, grew with 14.52 %.
In
2014 the assets of the company were 14.13 % composed of fixed assets and 85.87 %
by current assets. The assets are being financed by an equity of 30.89 %, and
total debt of 69.11 %.
In
2013 the assets of the company were 18.79 % composed of fixed assets and 81.21
% by current assets. The assets are being financed by an equity of 6.75 %, and
total debt of 93.25 %.
Year 2014
2013
Net turnover 254.508.000 294.355
Cost of sales 252.959.000 256.647
Gross margin 1.549.000 37.708
Operating expenses 63.318.000 73.191
Operating result -61.769.000 -35.483
Financial result -13.323.000
505
Result on ordinary operations before
Taxes -75.092.000
-34.978
Taxation on the result of ordinary
Activities 19.314.000 5.398
Result of ordinary activities after
taxes -55.778.000 -29.580
Net result -55.778.000 -29.580
Attributable to shareholders -55.778.000 -29.580
Summary The turnover of the company decreased by -13.54 % between 2013
and 2014.
The gross profit of the company decreased by -95.89 % between
2013 and 2014.
The operating result of the company declined with -74.08 %
between 2013 and 2014. This evolution implies an decrease of the company's
economic profitability.
The result of these changes is a reduction of the company's
Economic Profitability of -110900 % of the analysed period, being equal to 2013
% in the year 2014.
This fall has contributed to a asset turnover decrease, whose
index evolved from -43.28 to a level of 0.38.
The Net Result of the company increased by -88.57 % between 2013
and 2014.
The company's Financial Profitability has been positively
affected by the financial activities in comparison to the EBITs behaviour. The
result of these variations is a profitability increase of -29850 % of the
analysed period, being -35.94 % in the year 2014.
The company's financial profitability has been positively
affected by its financial structure.
The company's Financial Profitability has been neutrally
affected by the financial activities in comparison to the EBITs behaviour. The
result of these variations is the unchanged profitability of the analysed
period, remaining unchanged at -0.12 % in the year 2013.
Branch (SBI) Manufacture of basic pharmaceutical products and
pharmaceutical preparations (21)
Region Kennemerland
In the
Netherlands 351 of the companies are registered with the SBI code 21
In the
region Kennemerland 14 of the companies are registered with the SBI code 21
In the
Netherlands 7 of the bankrupcties are published within this sector
The
risk of this specific sector in the Netherlands is normal
The
risk of this specific sector in the region Kennemerland is normal
Filings 28-07-2015: De jaarrekening over 2013 is
gepubliceerd.
28-07-2015: De jaarrekening over 2014 is
gepubliceerd.
Functions 28-08-2014: Per 01-08-2014 is bestuurder Johannes
Paulus
Dalderop
in functie getreden.
20-08-2014:
Per 01-08-2014 is bestuurder Henri Pieter
Josephus
Henrichs in functie getreden.
20-08-2014:
Per 01-08-2014 is bestuurder Emile Gerardus
Wilhelmus
Hendricus Loof uit functie getreden.
10-07-2012:
Per 03-07-2012 is gevolmachtigde Denise van
Schooten
uit functie getreden.
06-07-2012:
Per 03-07-2012 is gevolmachtigde Mirjam
Anselma
Ince-Groenhof in functie getreden.
06-07-2012:
Per 03-07-2012 is gevolmachtigde Jan Willem
van
Wijk in functie getreden.
06-07-2012:
Per 03-07-2012 is gevolmachtigde Johanna
Maria
Maaskant in functie getreden.
Mergers 04-12-2013: Op 06-11-2013 fusieakte verleden.
Verkrijgende
rechtspersoon: Pharmachemie B.V.,
34016881
Verdwijnende rechtspersonen: Farmaver B.V.,
34088047
B.V. Pharbita, 35009579 PCH Vastgoed B.V.,
30091675
... Op 06-11-2013 fusieakte verleden.
Verkrijgende
rechtspersoon: Pharmachemie B.V.,
34016881
Verdwijnende rechtspersonen: IVAX Farma
B.V.,
34193015 Cephalon B.V., 17169815.
02-10-2013:
Op 30-09-2013 fusievoorstel gedeponeerd.
Verkrijgende
rechtspersoon: Pharmachemie B.V.,
34016881
Verdwijnende rechtspersonen: Farmaver B.V.,
34088047
B.V. Pharbita, 35009579 PCH Vastgoed B.V.,
30091675
... Op 30-09-2013 fusievoorstel gedeponeerd.
Verkrijgende
rechtspersoon: Pharmachemie B.V.,
34016881
Verdwijnende rechtspersonen: IVAX Farma
B.V.,
34193015 Cephalon B.V., 17169815.
Amendments 21-11-2014: Per 19-11-2014 statuten gewijzigd.
Relations 11
Show complete structure
5
Basel Street
49131
Petah Tiqva
Israel
Piet
Heinkade 107
1019GM
Amsterdam
Netherlands
Registration
number: 301106250000
Piet Heinkade
107
1019GM
AMSTERDAM
Netherlands
Registration
number: 300694240000
Swensweg
5
2031GA
Haarlem
Netherlands
Registration
number: 300993690001
Cacaoweg
20
1047BM
AMSTERDAM
Netherlands
Registration
number: 564734430000
Piet
Heinkade 107
1019GM
AMSTERDAM
Netherlands
Registration
number: 301751930000
Piet
Heinkade 107
1019GM
AMSTERDAM
Netherlands
Registration
number: 590121610000
Swensweg
5
2031GA
HAARLEM
Netherlands
Registration
number: 302098140000
Swensweg
5
2031GA
Haarlem
Netherlands
Registration
number: 340168810000
Swensweg
5
2031GA
HAARLEM
Netherlands
Registration
number: 300636290000
Swensweg
5
2031GA
HAARLEM
Netherlands
Registration
number: 340961910000
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.65.25 |
|
|
1 |
Rs.102.25 |
|
Euro |
1 |
Rs.72.20 |
INFORMATION DETAILS
|
Analysis Done by
: |
KIN |
|
|
|
|
Report Prepared
by : |
SDA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation
is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.